Advanced Solutions
for Advanced Pathology
TCL1 (MRQ-7)
Mouse Monoclonal Antibody
Cat. No. Description
Volume
45338 IMPATH TCL1 RTU M (MRQ-7)
50 Tests
44395 TCL1 RTU M (MRQ-7)
7 ml Ready To Use
44809 TCL1 0,1 M (MRQ-7)
100 µl liquid Concentrated
44810 TCL1 1 M (MRQ-7)
1 ml liquid Concentrated
Product Specifications
Designation
IVD
Reactivity
Paraffin
Visualization
Cytoplasmic, Nuclear
Control
B-cell Lymphoma, Tonsil
Stability
Up to 36 mo. at 2-8°C
Isotype
IgG
Manual Protocol*
• Pretreatment: Heat Induced Epitope
Retrieval (HIER)
• Primary Antibody Incubation Time:
10-30min @ 25-37°C
• 2-step polymer detection
*Please refer to product insert for complete protocol.
ImPath Protocol*
• Dewax: Dewax Solution 2 (DS2)
• Pretreatment: Retrieval Solution pH 9.0
(TR1) 32min @ 98-103°C
• Primary Antibody Incubation Time:
10-90min @ 25-37°C
• HRP Polymer (Universal) or AP Polymer
(Universal) for 12 min
*Please refer to product insert for complete protocol.
Product Description
T-cell leukemia/lymphoma protein 1 (TCL1, TCL1A, p14TCL1) is a 14 kDa product of the TCL1 gene that is involved in T-cell prolymphocytic
leukemia (T-PLL). TCL1 protein is normally found in the nucleus and cytoplasmof lymphoid lineage cells during early embryogenesis. Chromosomal
translocations may lead to overexpression of TCL1, resulting in T-cell leukemia and B-cell lymphoma. TCL1 binds to a novel site in the pleckstrin
homology (PH) domain, resulting in activation and nuclear translocation of Akt by overexpressed TCL1 which may promote an anti-apoptotic
response; this may normally serve to promote growth during development but may lead to malignancy when TCL1 is overexpressed. TCL1 is
expressed in differentiated B-cells under both reactive and neoplastic conditions, antigen committed B-cells, and in germinal center B-cells.
TCL1 is down-regulated in the latest stage of B-cell differentiation.
TCL1 is overexpressed in Burkitt lymphoma, the majority of AIDS-related non-Hodgkin lymphoma-designated immunoblastic plasmacytoid
lymphoma, lymphoblastic lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma, follicular lymphoma, diffuse large B-cell lymphoma,
and primary cutaneous B-cell lymphoma. Therefore, the most useful application of anti-TCL1 is the discrimination of B-cell lymphomas from
T-cell lymphomas, CD30+ anaplastic large cell lymphomas, multiple myeloma, and marginal zone B-cell lymphoma.
B-cell Lymphomas
TCL1 Annexin
A1
CD79a PAX-5
BCL6
CD5
CD10
CD23 Cyclin D1 MUM1
Follicular
+
-
+
+
+
-
+
-
-
-
CLL/SLL
+
-
+
+
-
+
-
+
-
+
Mantle Cell
+
-
+
+
-
+
-
-
+
-/+
Marginal Zone
-
-
+
+
-
-
-
-
-
+
Lymphoplasmacytic
+
-
+
+
-
-
-
-
-
+
Diffuse Large Cell
+
-
+
+
+
-/+
-/+
-
-
+
Burkitt
+
-
+
+
+
-
+
-
-
-
Hairy Cell Leukemia
+
+
+
-
-
-
-
+(weak)/-
T-cell Lymphomas
TCL1
CD2
CD3
CD25 CD45RO CD7
CD8
CD4
CD5
PD-1
NK
+
+
+
+
+
-/+
-
-
-
-
Reference
1. Roos J, et al. Pathobiology. 2001; 69(2):59-66.
2. Pescarmona E, et al. Histopathology. 2006 Oct; 49(4):343-8.
225
